Clayton Dubilier

PharMEDium sale a big deal for Oak

January 29, 2014: 1:41 PM ET

download (2)Source: Pharmacy compounding company valued at $900 million.

FORTUNE -- Private equity firm Clayton Dubilier & Rice today said that it has completed its previously-announced acquisition of a majority stake in PharMEDium from Oak Investment Partners and Baird Capital.

No financial terms were disclosed, but Fortune has learned that the deal was done at around a $900 million enterprise valuation.

For Oak this represents around a 6x return on its 2007 investment, when it paid around $67 million to acquire an equity stake from Baird (which retained part of its position).

PharMEDium is a Lake Forrest, Ill.–based provider of hospital pharmacy sterile compounding services.

Sign up for Dan Primack's daily email newsletter on deals and deal-makers:

  • Did private equity hurt Hertz?

    Is Hertz better off today than it was seven years ago?

    FORTUNE -- Hertz's private equity sponsors sold their remaining shares earlier this week, fully existing the company more than 7 years after buying it from Ford Motor Co. (F).

    That deal came in the midst of private equity's "golden age," and was one of that era's most-criticized transactions. Not so much the original purchase, but rather the subsequent $1 billion dividend MORE

    - May 9, 2013 3:35 PM ET
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by VIP.